Covid-like bat virus discovered by researchers at Wuhan lab in China

The study was led by Shi Zhengli, Chinese virologist from the controversial Wuhan Institute of Virology (WIV), where the Covid-19 was alleged to have emanated from

JN.1, JN.1 covid, covid
The latest discovery is a new lineage of the HKU5 coronavirus first identified in the Japanese pipistrelle bat in Hong Kong. | Photo: Freepik
Press Trust of India
3 min read Last Updated : Feb 22 2025 | 9:04 AM IST
A Chinese team of virologists have found a new bat coronavirus that carries the risk of animal-to-human transmission because it uses the same human receptor as the virus that causes Covid-19, a media report said.
 
The study was led by Shi Zhengli, Chinese virologist from the controversial Wuhan Institute of Virology (WIV), where the Covid-19 was alleged to have emanated from.
 
Shi, who is known as the Bat Woman for her research on viruses from the Bats, as well as the Chinese government deny that the virus was leaked from the Wuhan lab.
 
The latest discovery is a new lineage of the HKU5 coronavirus first identified in the Japanese pipistrelle bat in Hong Kong.
 
The new virus comes from the merbecovirus subgenus, which also includes the virus that causes Middle East respiratory syndrome (Mers), the Hong Kong based South China Morning Post reported.
 
The virus is able to bind to the human angiotensin converting enzyme (ACE2), the same receptor used by the Sars-CoV-2 virus, which causes Covid-19, to infect cells.
 
We report the discovery and isolation of a distinct lineage (lineage 2) of HKU5-CoV, which can utilise not only bat ACE2 but also human ACE2 and various mammalian ACE2 orthologs [ genes found in different species with a common origin], the team of virologists headed by Shi wrote in a paper published in the peer-reviewed journal Cell on Tuesday, according to the Post report.
 
The researchers found that when the virus was isolated from bat samples it could infect human cells as well as artificially grown masses of cell or tissue that resembled miniaturised respiratory or intestinal organs.
 
Earlier this month, China said its bio-lab in Wuhan which faced allegations leaking the COVD-19 causing the global pandemic has never engaged in gain-of-function studies on coronavirus amid allegations that USAID has funded the study of the infectious disease.
 
China has also made it clear more than once that the Wuhan Institute of Virology has never engaged in gain-of-function studies of coronavirus, Chinese Foreign Ministry spokesperson Guo Jiakun told a media briefing here responding to allegations in US that the USAID taxpayers' money was used to fund gain-of-function studies at the Chinese bio-lab.
 
Gain-of-function research is medical research that genetically alters an organism in a way that may enhance the biological functions of gene products.
 
Never has it designed, made or leaked COVID-19. On the origins-tracing of the virus, China firmly opposes all forms of political manipulation, Guo said.
 
According to recent American media reports, the US Agency for International Development (USAID) used taxpayers' money to fund gain-of-function studies at China's Wuhan Institute of Virology, which may have caused the COVID-19 pandemic, leading to the deaths of millions around the world.
 
Trump has shut down the USAID work that was not aligned with American strategic interests and wastes money.
 
The Wuhan bio-lab was constantly under scanner, especially during the previous Trump presidency.
 
Guo said at a media briefing on February 12 here that It is 'extremely unlikely' that the COVID-19 pandemic was caused by a lab leak this is the authoritative conclusion reached by the experts of the WHO-China joint mission based on science following their field trips to the lab in Wuhan and in-depth communication with researchers.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsChinaResearchVirusesCOVID-19

First Published: Feb 22 2025 | 9:04 AM IST

Next Story